AT&T Selects STREAMWIDE to Power the FirstNet Next-Generation Mission-Critical Application for Public Safety in the U.S.
30.9.2025 17:45:00 CEST | Business Wire | Press Release
AT&T has selected STREAMWIDE to power its next-generation mission-critical solution for FirstNet®, Built with AT&T, the only network built with and for America’s first responders. Currently FirstNet supports more than 30K public safety agencies and organizations.
Based on the 3GPP standard for mission-critical services (MCX), which includes push-to-talk, video, data, and command & dispatch, the solution introduces next-generation capabilities that go far beyond traditional radio networks currently used by first responders, including police, fire, EMS, and other critical services.
Through this collaboration, AT&T integrates STREAMWIDE’s field-proven mission-critical technology into its portfolio, creating a cutting-edge solution designed for the most demanding environments.
Key benefits for public safety and mission-critical organizations include:
- 3GPP-compliant MCX services offering push-to-talk, secure multimedia, geolocation, real-time video, secure messaging, and more – across a large portfolio of devices.
- Massive-scale interoperability using the standards based InterWorking Function (IWF) technology, enabling communication between next-generation broadband users and virtually any land mobile radio system — marking the world’s first large-scale deployment of IWF under 3GPP standards.
- Enable a smooth transition from Land Mobile Radio systems, such as P25, to advanced 4G and 5G cellular platforms.
- Priority and preemption for first responders on the FirstNet network.
- Demonstrated reliability with multiple geo-redundant platforms across the U.S.
This project marks a breakthrough for STREAMWIDE in the U.S, underlining the trust placed by a major public safety operator in its technology. STREAMWIDE solutions have already been successfully deployed and validated by public safety organizations and first responders in Europe and other continents, and this contract confirms their global leadership.
Pascal Beglin, CEO of STREAMWIDE, commented:
“We are proud to deliver world-class mission-critical technology. This collaboration with a global telecom leader and a leading public safety organization further demonstrates the confidence placed in our solutions. It highlights the maturity of our technology and the unique value we bring in helping agencies migrate smoothly to innovative 4G/5G platforms, while ensuring full interoperability with their existing systems. We are honored to bring this new technology to the Public Safety communities.”
Pascal Beglin, CEO of STREAMWIDE, added:
“Being selected by AT&T to deliver mission-critical services for such a large-scale public safety project is a tremendous recognition of our expertise. With more than 30,000 public safety agencies and organizations on FirstNet, this deployment will serve as a global reference, showcasing STREAMWIDE’s ability to deliver innovation, resilience, and security at scale.”
Matt Walsh, AVP Product, FirstNet and Next Generation 9-1-1 said:
“As public safety’s partner, we are always looking for the best collaborators to innovate for first responders. We strive to create better platforms and evolve with the needs of public safety. STREAMWIDE’s proven record will help us give America’s public safety community the flexibility to adapt to whatever emergency they might face.”
With this collaboration, STREAMWIDE and AT&T will reaffirm their leadership in mission-critical communications. Together, they are committed to delivering secure, reliable, and future-ready technology to those who protect communities and manage critical operations every day.
FirstNet and the FirstNet logo are registered trademarks and service marks of the First Responder Network Authority. All other marks are the property of their respective owners.
About STREAMWIDE (Euronext Growth: ALSTW - FR0010528059)
STREAMWIDE is a recognized global leader in secure, mission-critical and business-critical communication solutions. Trusted by public safety agencies and enterprises worldwide, STREAMWIDE delivers innovative platforms that combine resilience, interoperability, and ease of use. Its solutions empower organizations in public safety, defense, energy, transportation, and industry to collaborate more efficiently, respond faster, and operate with maximum security in the most demanding environments.
For more information, visit us at http://www.streamwide.com
Investors can learn more at : www.streamwide.com/en/investors/
About AT&T
We help more than 100 million U.S. families, friends and neighbors, plus nearly 2.5 million businesses, connect to greater possibility. From the first phone call 140+ years ago to our 5G wireless and multi-gig internet offerings today, we @ATT innovate to improve lives. For more information about AT&T Inc. (NYSE:T). Please visit us at about.att.com. Investors can learn more at investors.att.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250930909125/en/
Contacts
Media
Lobna Hermi
STREAMWIDE Corporate Communications
T +33 1 70 22 01 01
lhermi@streamwide.com
Megan Frye
AT&T Corporate Communications
Phone : (469) 841-5012
megan.frye@att.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom